IMV Inc. (IMV)
| Market Cap | 235.90M |
| Revenue (ttm) | 433,588 |
| Net Income (ttm) | -20.89M |
| Shares Out | 49.65M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $3.66 |
| Previous Close | $3.54 |
| Change ($) | 0.12 |
| Change (%) | 3.39% |
| Day's Open | 3.46 |
| Day's Range | 3.37 - 3.69 |
| Day's Volume | 231,264 |
| 52-Week Range | 1.40 - 5.95 |
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vac...
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - On national TV Sat. Dec 12 & Sun. Dec 13, 2020 - BTV-Business Television spotlights the newest mining, cannabis, tech and ph...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies ...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines a...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...
IMV Inc. (IMV) CEO Frederic Ors on Q3 2020 Results - Earnings Call Transcript
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the Comp...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers
HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Appili Announces Additional $6.3MM US Funding for its ATI-1701 Biodefense Program, working with Ology Bio on a vaccine cand...
HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Investigators enrolled and dosed the first cluster of participants in Appili's Phase 2 CONTROL clinical trial evaluating fa...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Re-establishes At-the-Market Facility
IMV has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...
Canada's IMV is a small but high-profile biotechnology company engaged in the development of a COVID-19 vaccine.
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against inf...
IMV Inc. (IMV) CEO Frederic Ors on Q2 2020 Results - Earnings Call Transcript
IMV INC (IMV) delivered earnings and revenue surprises of 25.00% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Second Quarter 2020 Financial Results
IMV is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
IMV INC (IMV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV (NASDAQ: IMV) shares are trading higher on Wednesday after the company announced it has received CA$4.75 million ($3.59 million) in funding from the Canadian government agencies for a COVI...
IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020
As of late, it has definitely been a great time to be an investor in IMV Inc. (IMV).
IMV saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Good news for Moderna was bad news for several of its rivals.
IMV Inc. (NASDAQ: IMV) shares surged on Tuesday after the company provided an update on its vaccine candidate for COVID-19.
Imv Inc (NASDAQ: IMV) share are ripping higher on above-average volume following an update by the company on its coronavirus vaccine program.
IMV Inc. (IMV) CEO Frederic Ors on Q1 2020 Results - Earnings Call Transcript
IMV INC (IMV) delivered earnings and revenue surprises of -27.27% and 27.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV, Inc. (IMV) CEO Frederic Ors on Q4 2019 Results - Earnings Call Transcript
Two coronavirus vaccine candidates are in the clinics and 42 more are in preclinical studies, according to updated data provided by the World Health Organization on March 20.
IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.
Micro-cap Canadian biopharma Imv Inc (NASDAQ: IMV) said Wednesday that it is advancing the clinical development of a DPX-based vaccine candidate for the coronavirus, joining a number of biotec...
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV, Inc. (IMV) CEO Frederic Ors on Q3 2019 Results - Earnings Call Transcript
IMV INC (IMV) delivered earnings and revenue surprises of -33.33% and 175.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV, Inc. (IMV) CEO Frederic Ors on Q2 2019 Results - Earnings Call Transcript
About IMV
IMV operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphom... [Read more...]
| Industry Biotechnology | Founded 2000 |
| CEO Frederic Ors M.B.A., B.Sc., M.A. | Employees 62 |
| Stock Exchange NASDAQ | Ticker Symbol IMV |
Financial Performance
In 2019, IMV Inc.'s revenue was 568,000, an increase of 17.60% compared to the previous year's 483,000. Losses were -27.37 million, 24.8% more than in 2018.